


In the Claims

1. (Currently Amended) A diazaspirononane compound having the following formula:

Formula I



and pharmaceutically acceptable salts thereof,

wherein Q^I is $(CZ_2)_u$, Q^{II} is $(CZ_2)_v$, Q^{III} is $(CZ_2)_w$, and Q^{IV} is $(CZ_2)_x$,


u , v , w and x are individually 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3,

and the values of u , v , w and x are selected such that the ring is a diazaspirononane,

R is hydrogen, lower alkyl, acyl, alkoxycarbonyl or aryloxycarbonyl,

Z is, individually, selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, ~~substituted heterocyclyl~~, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl and substituted arylalkyl;

Cy is a six membered ring of the formula:



where one of X , X' , X'' , X''' and X'''' is nitrogen, and the others are carbon bonded to a

substituent species,

wherein "substituent species" are, individually, selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, ~~heterocyclyl, substituted~~ heterocyclyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, halo, -OR', -NR'R'', -CF₃, -CN, -NO₂, -C₂R', -SR', -N₃, -C(=O)NR'R'', -NR'C(=O)R'', -C(=O)R', -C(=O)OR', -OC(=O)R', -O(CR'R'')_rC(=O)R', -O(CR'R'')_rNR''C(=O)R', -O(CR'R'')_rNR''SO₂R', -OC(=O)NR'R'', -NR'C(=O)OR'', -SO₂R', -SO₂NR'R'', and -NR'SO₂R'',

where R' and R'' are individually hydrogen, C₁-C₈ alkyl, cycloalkyl, ~~heterocyclyl~~, aryl, or arylalkyl, and r is an integer from 1 to 6, or R' and R'' can combine to form a cyclic functionality, and

wherein the term "substituted" as applied to alkyl, aryl, cycloalkyl and the like refers to the substituents described above, starting with halo and ending with -NR'SO₂R''.

Claims 2-3. (Cancelled)

4. (Previously Presented) The compound of claim 1, wherein X''' is nitrogen.

Claim 5. (Cancelled)

6. (Original) The compound of claim 1, wherein X, X'' and X''' are carbon bonded to a substituent species.

7. (Original) The compound of claim 6, where the substituent species at X, X'' and X''' are hydrogen.

Claims 8-10. (Cancelled)

11. (Previously Presented) A pharmaceutical composition including a compound of claim 1 along with a pharmaceutically acceptable carrier.

Claims 12-40. (Cancelled)

41. (Previously Presented) A compound selected from the group consisting of:

- 7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-(1,2,4-oxadiazolyl))-1,7-diazaspiro[4.4]nonane
- 7-(2-(1,3,4-oxadiazolyl))-1,7-diazaspiro[4.4]nonane
- 7-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane
- 7-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-methoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-cyclopentyloxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-(4-hydroxyphenoxy)-3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(5-ethynyl-3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(6-chloro-3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 7-(6-methoxy-3-pyridazinyl)-1,7-diazaspiro[4.4]nonane
- 1-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
- 1-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane
- 1-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane
- 1-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane
- 1-(5-(1,2,4-oxadiazolyl))-1,7-diazaspiro[4.4]nonane

1-(2-(1,3,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane
1-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane
1-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-(1,2,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(2-(1,3,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-methoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-cyclopentyloxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-(4-hydroxyphenoxy)-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(5-ethynyl-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(6-chloro-3-pyridyl)-1,7-diazaspiro[4.4]nonane
1-methyl-7-(6-methoxy-3-pyridazinyl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(3-pyridyl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(5-pyrimidinyl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(5-isoxazolyl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(5-isothiazolyl)-1,7-diazaspiro[4.4]nonane

7-methyl-1-(5-(1,2,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(2-(1,3,4-oxadiazol)yl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(2-pyrazinyl)-1,7-diazaspiro[4.4]nonane
7-methyl-1-(3-pyridazinyl)-1,7-diazaspiro[4.4]nonane
2-(3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-pyrimidinyl)-2,7-diazaspiro[4.4]nonane
2-(5-isoxazolyl)-2,7-diazaspiro[4.4]nonane
2-(5-isothiazolyl)-2,7-diazaspiro[4.4]nonane
2-(5-(1,2,4-oxadiazol)yl)-2,7-diazaspiro[4.4]nonane
2-(2-(1,3,4-oxadiazol)yl)-2,7-diazaspiro[4.4]nonane
2-(2-pyrazinyl)-2,7-diazaspiro[4.4]nonane
2-(3-pyridazinyl)-2,7-diazaspiro[4.4]nonane
2-(5-methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-cyclopentyloxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-(4-hydroxyphenoxy)-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(5-ethynyl-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(6-chloro-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-(6-methoxy-3-pyridazinyl)-2,7-diazaspiro[4.4]nonane
2-methyl-7-(3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-methyl-7-(5-methoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane
2-methyl-7-(5-phenoxy-3-pyridyl)-2,7-diazaspiro[4.4]nonane

6-(3-pyridyl)-1,6-diazaspiro[3.5]nonane

1-methyl-6-(3-pyridyl)-1,6-diazaspiro[3.5]nonane

2-(3-pyridyl)-2,5-diazaspiro[3.5]nonane

5-methyl-2-(3-pyridyl)-2,5-diazaspiro[3.5]nonane and
pharmaceutically acceptable salts thereof.

Claim 42. (Cancelled)

43. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound of claim 41 along with a pharmaceutically acceptable carrier.

Claim 44. (Cancelled)